Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Date:8/5/2009

NEW YORK, Aug. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer (the "Company"), today announced its results for the second quarter ended June 30, 2009.

At June 30, 2009, the Company had cash, cash equivalents, short-term investment securities and interest receivable of $13.4 million, as compared to $15.5 million at December 31, 2008. In addition, at June 30, 2009, the Company had $7.1 million of auction rate securities which are classified as long-term investments. Additionally, in July 2009, the Company received $2.75 million of cash from a settlement with the former licensor of Sulonex (sulodexide). The Company will receive an additional $750,000 on or before July 30, 2010 related to this settlement.

The net income for the second quarter ended June 30, 2009 was $14.1 million, or $0.29 per diluted share, compared to a net loss of $7.7 million, or $0.17 per share, for the second quarter in 2008. The change in net income (loss) was primarily attributable to the recognition of $18.0 million in license revenue relating to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii), which eliminated the Company's significant ongoing obligations included in the original agreement, a $1.8 million decrease in research and development expenses related to KRX-0401, and a $1.0 million decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008.

The net income for the six months ended June 30, 2009 was $14.6 million, or $0.30 per diluted
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013  (PSHR) Pacific ... naturally based products across a broad range of ... has retained investor relations firm, BlueWater Advisory Group, ... return to trading process, and to direct the ... initiation. Matthew Mills ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 With bed bugs' ... said that although bed bugs need to be eliminated, one ... not compromise a person's health. And so to help bed ... to get rid of bed bugs without using ... bed bug spray it called Bed Bug Bully. , According ...
(Date:5/20/2013)... , May 20, 2013   Flexion Therapeutics ... Frederick W. Driscoll to its management team ... 30 years of financial management experience with biotechnology and ... Mr. Driscoll was chief financial officer for Novavax (NASDAQ: ... that secured more than $250 million through a combination ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Researchers from the ... the connection between lower back pain, and the acne causing ... in the system the bacteria seek out oxygen deprived location ... in the spinal column, P.acnes has the ability to live ... , Fernando Perez, a spokesman for “ The best acne ...
Breaking Biology Technology:Pacific Shore Holdings Retains Investor Relations Firm 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2
... 20 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) ... as Senior Vice President and Chief Medical Officer. ... development and registration of cancer,therapeutics and has had ... and clinical pharmacologist, most notably at Novartis. Dr. ...
... are making a considerable impact on many aspects ... Reaching for the human frontier, robotics is also ... emerging domains. Interacting, exploring, and working with humans, ... peoples lives. The prospect of practical robots among ...
... 19 Mass spectrometry, driven by,a broad range of ... an increasing number of applications in the clinic, according,to ... Engineering and Biotechnology,News (GEN) ( http://www.genengnews.com ). Mass spec ... to a growing focus on screening patients through,the identification ...
Cached Biology Technology:Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer 2Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer 3Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer 4Robots moving closer to humans 2Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery 2
(Date:5/21/2013)... charted the path of insulin action in cells in ... blueprint for understanding what goes wrong in diabetes. ... Professor David James from Sydney,s Garvan Institute of Medical ... of the prestigious journal Cell Metabolism . , ... very important role in the body because it helps ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
(Date:5/20/2013)... popularly known as the lungs of the planet, inhales carbon ... the air to grow parts that eventually fall to the ... plentiful rainfall. , Until recently people believed much of ... ended up deep in the ocean. University of Washington research ... carbon dioxide though left open the question of how ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3
... TGen Drug Development (TD2) and the Institut ... will enable both to maximize their worldwide contributions ... The partnership between TD2, a Scottsdale subsidiary of ... Marseille, France-based IPC,s comprehensive cancer center will enable ...
... University Medical Center in New York have confirmed that ... not a descendant of healthy humans dwarfed by disease. ... specimen, researchers determined the "hobbit" to be a distinct species ... Details of the study appear in the December issue of ...
... a step toward using human saliva to tell whether those ... are normal or red flags for disease, scientists are describing ... age. The discovery could lead to a simple, noninvasive test ... they suggest in a report in ACS, Journal of ...
Cached Biology News:TGen Drug Development establishes European footprint 2'Hobbits' are a new human species -- according to the statistical analysis of fossils 2
Glutamate Receptor 5/1a...
Ly-49C and Ly-49I Biotin Anti-Mouse clone 5E6, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Gentamicin sulfate, 5g...
Biology Products: